DiscoveryProbe™ FDA-approved Drug Library: Benchmarks, Mechanisms, and Workflow Integration

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically approved small molecules, including enzyme inhibitors, receptor modulators, and pathway regulators, in 10 mM DMSO solutions (APExBIO, 2024). All compounds are approved by at least one major regulatory agency (FDA, EMA, HMA, CFDA, or PMDA) or listed in recognized pharmacopeias. The library supports high-throughput and high-content screening (HTS/HCS) for drug repositioning and mechanistic discovery, as demonstrated by studies revealing novel targets such as SDC4 in cancer cells (Cui et al., Am J Cancer Res 2022). Pre-dissolved DMSO format guarantees stability for 12–24 months at -20°C to -80°C, supporting reproducibility in translational research. Representative drugs include doxorubicin, metformin, atorvastatin, and eltrombopag, each with well-documented pharmacological profiles.

Biological Rationale

Screening clinically approved compounds accelerates drug discovery by leveraging established safety and pharmacokinetic profiles (APExBIO). The DiscoveryProbe™ FDA-approved Drug Library enables systematic interrogation of disease pathways using small molecules that modulate diverse biological targets. For example, eltrombopag, originally an agonist of the thrombopoietin receptor, has been shown to bind SDC4 and modulate oncogenic signaling in cancer cells (Cui et al., 2022). This demonstrates the library's utility for uncovering novel molecular interactions and facilitating drug repositioning.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library contains compounds with diverse mechanisms, including:

• Receptor agonists/antagonists: Modulate GPCRs, nuclear hormone receptors, and tyrosine kinase receptors (e.g., doxorubicin, eltrombopag).
• Enzyme inhibitors: Target kinases, proteases, and metabolic enzymes (e.g., metformin, atorvastatin).
• Ion channel modulators: Affect cardiac and neuronal signaling.
• Signal pathway regulators: Influence MAPK, PI3K/AKT, and other critical signaling cascades (related analysis).

The inclusion of FDA, EMA, and other agency-approved drugs ensures that each compound's mechanism is well-characterized and supported by preclinical and clinical evidence.

Evidence & Benchmarks

• All 2,320 compounds are approved by at least one regulatory authority (FDA, EMA, HMA, CFDA, PMDA) or listed in major pharmacopeias (APExBIO).
• Eltrombopag (SB-497115), included in the library, directly binds SDC4 (Kd ≈ 2 μM) and enhances MAPK signaling and macropinocytosis in pancreatic cancer cells (Cui et al., 2022).
• Stable DMSO solutions (10 mM) provided in 96-well microplates, deep well plates, or barcoded storage tubes; stability confirmed for 12 months at -20°C and up to 24 months at -80°C (APExBIO).
• Used in quantitative ligand interaction screening and high-throughput phenotypic assays for oncology, neurodegeneration, and virology (see rapid antiviral screening).
• Validated in CRISPR/Cas9-edited cell lines (e.g., SDC4 knockout in PANC1, HCT116) to map drug–target interactions (Cui et al., 2022).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is suited for:

• High-throughput drug screening (HTS) and high-content screening (HCS) in oncology, neurodegeneration, and infectious disease research.
• Drug repositioning and identification of novel pharmacological targets, as shown by SDC4–eltrombopag interaction studies (Cui et al., 2022).
• Signal pathway regulation and mechanistic studies across multiple cell types and disease models (further workflow insights).
• Assay development for GPCRs, kinases, and metabolic pathways.

Common Pitfalls or Misconceptions

• Not all compounds are equally potent across all targets: Only validated targets/mechanisms should be assumed; repurposing outside these contexts requires experimental confirmation.
• Compound solubility and DMSO compatibility: While all compounds are pre-dissolved in DMSO, some may precipitate upon dilution or under specific assay conditions.
• No coverage for experimental or investigational drugs: The library excludes compounds lacking clinical approval or pharmacopeia listing.
• Does not replace disease model validation: Library screening identifies hits, but mechanism and efficacy must be validated in disease-relevant models.
• Not suitable for in vivo screening without re-validation: Formulations and doses are optimized for in vitro use; in vivo application requires pharmacokinetic and toxicity assessments.

Workflow Integration & Parameters

The entire DiscoveryProbe™ FDA-approved Drug Library is pre-dissolved at 10 mM in DMSO and distributed in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes for streamlined automation (APExBIO). Solutions are stable for 12 months at -20°C and up to 24 months at -80°C. Shipping is performed on blue ice for evaluation samples, and at room temperature or blue ice upon request. Typical HTS protocols use 1–10 μM final compound concentrations with appropriate controls. The library's barcoded format supports LIMS integration and traceable compound management.

For practical guidance on cell-based assay integration and troubleshooting, see this article, which details real-world challenges and solutions not fully explored in this overview.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO provides a robust, mechanism-rich resource for accelerating drug repositioning, pharmacological target discovery, and disease modeling. By leveraging 2,320 fully annotated, stable compounds, researchers can systematically interrogate signaling pathways and disease targets in high-throughput and high-content formats. Recent studies, such as the identification of SDC4 as a novel eltrombopag target, underscore the library's potential for translational breakthroughs. For further reading on advanced mechanism-based screening and translational impact, this article extends the discussion beyond this overview.

For full product specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library page.